sto-3 Antibody
Description
Contextual Clarification
| Trial Arm | 70-Gene High Risk (n=167) | 70-Gene Low Risk (n=371) | Total Patients |
|---|---|---|---|
| Tamoxifen-Treated | 82 | 199 | 281 |
| Untreated | 85 | 172 | 257 |
STOML3 Antibody
A commercially available antibody targeting STOML3 (stomatin-like protein 3) is documented in proteomics databases :
| Property | Detail |
|---|---|
| Host Species/Isotype | Rabbit IgG |
| Reactivity | Human, Mouse, Rat |
| Applications | WB (1:500–1:2000), IHC, IF |
| Molecular Weight | Observed: 30 kDa; Calculated: 32 kDa |
| Immunogen | STOML3 fusion protein (amino acids 1–291) |
| Storage | -20°C in PBS with 0.02% sodium azide and 50% glycerol |
This antibody has been validated in Western blot (HeLa, MCF-7 cells) and immunohistochemistry .
SST3 (Somatostatin Receptor 3) Antibody
Another candidate is the SST3 antibody (7TM0357N-IC), which targets the carboxyl-terminal tail of somatostatin receptor 3 :
Key Research Findings:
-
Uniform plasma membrane localization in pituitary adenomas (Figures 1–2) .
-
Internalization into perinuclear vesicles upon somatostatin exposure (Figure 3) .
STO-3 Trial Antibody-Related Insights
While the STO-3 trial focused on tamoxifen, its companion studies utilized antibodies for biomarker analysis:
-
ER/PR Status: Immunohistochemical assays classified hormone receptor status .
-
HER2 Testing: Monoclonal antibodies identified HER2-positive tumors .
20-Year Survival Outcomes by Risk Category :
| Risk Group | Tamoxifen-Treated BCSS (20-yr) | Untreated BCSS (20-yr) | Hazard Ratio (95% CI) |
|---|---|---|---|
| 70-Gene High | 83% | 65% | 0.42 (0.21–0.86) |
| 70-Gene Low | 90% | 80% | 0.46 (0.25–0.85) |
Product Specs
**Constituents:** 50% Glycerol, 0.01M PBS, pH 7.4
